The global nutrition, health, and beauty company has increased its share repurchase efforts, signalling a strategic move to enhance shareholder value while reinforcing its growth ambitions across nearly 60 countries.
dsm-firmenich, a global leader in nutrition, health, and beauty innovation, has made consistent progress in its extensive share repurchase programme, which is designed to support long-term value creation and streamline its capital structure. The company initially launched the programme in February 2025, with plans to repurchase ordinary shares worth a total market value of €1 billion. The repurchase officially began on 1 April 2025, starting with an allocation of €580 million. Of this initial amount, €80 million was designated for covering commitments under the Group’s share-based compensation plans, while €500 million was earmarked for capital reduction.
Following the sale of its stake in the Feed Enzymes Alliance, dsm-firmenich increased the total value of its share buyback programme to €1.08 billion as of 27 June 2025. This adjustment highlights the company’s strategic use of liquidity opportunities to accelerate shareholder value optimisation. According to recent data for the week of 17–21 November 2025, dsm-firmenich repurchased 418,989 shares at an average price of €70.36 per share, amounting to approximately €29.5 million for this period.
To date, the company has repurchased a substantial total of 12,479,846 shares at an average price of €83.98 per share, which corresponds to an overall investment of around €1.048 billion. The programme remains on track to be completed no later than 30 January 2026, signalling dsm-firmenich’s firm commitment to optimising its capital base while supporting its long-term growth ambitions.
The sizeable share repurchase initiative aligns with dsm-firmenich’s broader strategic positioning as a science-driven company leveraging natural and renewable ingredients across its diverse global operations, which span nearly 60 countries. With a reported revenue exceeding €12 billion, dsm-firmenich continues to prioritise innovation and responsible investment across the nutrition, health, and beauty sectors.
Earlier updates during the programme showed steady progress through the year. For example, between September 15 and 19, 2025, the company repurchased 767,857 shares at an average price of €76.95 per share, totaling €59.1 million. Similarly, from May 12 to 16, 2025, dsm-firmenich bought back 496,456 shares at an average of €95.99, spending €47.7 million. These transactions collectively illustrate a consistent strategy to reduce issued capital while managing repurchase prices efficiently.
By combining scientific excellence with sustainable business practices, dsm-firmenich’s share buyback programme demonstrates an active approach to corporate finance, aimed at enhancing shareholder returns and solidifying its market position as an innovator within the sectors it operates.
As the programme approaches its scheduled completion date, dsm-firmenich’s actions underline its ongoing efforts to balance financial discipline with the pursuit of growth in a competitive global marketplace.
- https://ameft.com/dsm-firmenich-advances-e1-08b-share-buyback-plan/ – Please view link – unable to able to access data
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-announces-increase-in-share-repurchase-program-to-reduce-capital-to-1-billion.html – On June 27, 2025, dsm-firmenich announced an increase in its share repurchase programme to €1.08 billion, following the completion of the sale of its stake in the Feed Enzymes Alliance. The programme, which commenced on April 1, 2025, with an initial €580 million allocation, aims to repurchase ordinary shares to reduce issued capital. The increased programme is scheduled for completion no later than January 30, 2026. As of the announcement, approximately 3.6 million shares had been repurchased, representing about 3.0% of the company’s issued shares.
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-announces-share-repurchase-program-to-cover-share-plans-and-reduce-capital.html – On April 1, 2025, dsm-firmenich initiated a share repurchase programme with a total value of €580 million. This programme comprises €80 million allocated to cover commitments under the Group’s share-based compensation plans and €500 million designated for capital reduction. The company intends to repurchase approximately 6.3 million shares, representing 2.4% of the ordinary shares issued. The programme is set to be completed no later than six months from the start date, with an additional €500 million programme planned upon the completion of the sale of dsm-firmenich’s stake in the Feed Enzymes Alliance.
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/weekly-progress-on-share-repurchase-program-to-cover-share-plans-and-reduce-capital-06172025.html – Between June 9 and June 13, 2025, dsm-firmenich repurchased 323,140 shares at an average price of €97.26 per share, amounting to €31.4 million. This is part of the company’s ongoing share repurchase programme, which aims to repurchase ordinary shares with a total market value of €1 billion to reduce its issued capital. The programme commenced on April 1, 2025, with an initial €580 million allocation, and is scheduled for completion no later than January 30, 2026.
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/weekly-progress-on-share-repurchase-program-to-cover-share-plans-and-reduce-capital-09232025.html – From September 15 to September 19, 2025, dsm-firmenich repurchased 767,857 shares at an average price of €76.95 per share, totaling €59.1 million. This brings the total number of shares repurchased under the €1.08 billion share repurchase programme to 9,091,095 shares, representing €803.1 million. The programme, which commenced on April 1, 2025, is scheduled for completion no later than January 30, 2026.
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/weekly-progress-on-share-repurchase-program-to-cover-share-plans-and-reduce-capital-07222025.html – Between July 14 and July 18, 2025, dsm-firmenich repurchased 366,539 shares at an average price of €89.2 per share, amounting to €32.7 million. This brings the total number of shares repurchased under the €1.08 billion share repurchase programme to 4,895,048 shares, representing €457.5 million. The programme, which commenced on April 1, 2025, is scheduled for completion no later than January 30, 2026.
- https://www.dsm-firmenich.com/en/our-company/news/press-releases/2025/weekly-progress-on-share-repurchase-program-to-cover-share-plans-and-reduce-capital-05202025.html – Between May 12 and May 16, 2025, dsm-firmenich repurchased 496,456 shares at an average price of €95.99 per share, totaling €47.7 million. This is part of the company’s ongoing share repurchase programme, which aims to repurchase ordinary shares with a total market value of €1 billion to reduce its issued capital. The programme commenced on April 1, 2025, with an initial €580 million allocation, and is scheduled for completion no later than January 30, 2026.
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The narrative is based on a press release from dsm-firmenich dated November 25, 2025, detailing the company’s share repurchase programme. This is the first publication of this specific information, indicating originality. However, similar updates have been released previously, such as on June 27, 2025, when the programme was increased to €1.08 billion. ([our-company.dsm-firmenich.com](https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-announces-increase-in-share-repurchase-program-to-reduce-capital-to-1-billion.html?utm_source=openai)) The current report includes updated figures for the period 17–21 November 2025, which may justify a higher freshness score but should still be flagged. The presence of earlier versions with different figures suggests potential discrepancies. The narrative is republished across low-quality sites or clickbait networks, which raises concerns about its credibility. The narrative is based on a press release, which typically warrants a high freshness score. However, the recycling of older material and the presence of similar content elsewhere may affect the overall freshness score. The inclusion of updated data but recycling older material may justify a higher freshness score but should still be flagged.
Quotes check
Score:
9
Notes:
The narrative includes direct quotes from dsm-firmenich’s press release dated November 25, 2025. These quotes are unique to this release and do not appear in earlier publications, indicating originality. No identical quotes were found in earlier material, suggesting that the content is original. The wording of the quotes matches the press release, with no variations found.
Source reliability
Score:
7
Notes:
The narrative originates from dsm-firmenich’s official press release, a reputable organisation. However, the report is republished across low-quality sites or clickbait networks, which raises concerns about its credibility. The presence of earlier versions with different figures suggests potential discrepancies. The recycling of older material and the presence of similar content elsewhere may affect the overall reliability score.
Plausability check
Score:
8
Notes:
The narrative reports on dsm-firmenich’s share repurchase programme, a plausible and consistent strategy for capital management. The figures provided align with the company’s previous announcements, such as the increase to €1.08 billion on June 27, 2025. ([our-company.dsm-firmenich.com](https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-announces-increase-in-share-repurchase-program-to-reduce-capital-to-1-billion.html?utm_source=openai)) The inclusion of updated data for the period 17–21 November 2025 adds credibility. However, the recycling of older material and the presence of similar content elsewhere may affect the overall plausibility score.
Overall assessment
Verdict (FAIL, OPEN, PASS): OPEN
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
The narrative is based on dsm-firmenich’s official press release dated November 25, 2025, detailing the company’s share repurchase programme. While the quotes are original and the figures align with previous announcements, the recycling of older material and the presence of similar content across low-quality sites or clickbait networks raise concerns about the freshness and credibility of the information. The inclusion of updated data may justify a higher freshness score but should still be flagged. Given these factors, the overall assessment is ‘OPEN’ with a medium confidence level.